Table 2

Baseline characteristics and therapy of non-diabetic patients based on quartiles of admission heart rate (Q1-Q4)
Patients without T2DM(n = 6474) P-value Patients with T2DM(n = 820) P-value
Q1(n = 1766) Q2(n = 1696) Q3(n = 1518) Q4(n = 1494) Q1(n = 180) Q2(n = 175) Q3(n = 193) Q4(n = 272)
Females, % 25.3 25.5 26.8 31.3 <0.001 37.8 43.4 42.0 47.1 0.270
Age 62.3 ± 11.2 61.2 ± 11.9 61.7 ± 12.2 63.0 ± 12.9 <0.001 64.5 ± 9.9 64.0 ± 9.5 64.8 ± 10.2 65.3 ± 9.9 0.313
Systolic blood pressure 120.0 ± 24.0 128.0 ± 24.0 130.4 ± 23.3 128.5 ± 28.0 <0.001 120.2 ± 26.8 130.2 ± 22.0 130.6 ± 25.2 130.1 ± 27.4 <0.001
Anterior ST Elevation, % 34.4 51.6 62.7 68.5 <0.001 27.2 50.3 57.5 67.3 <0.001
Killip class ≥2, % 13.5 12.6 14.0 29.7 <0.001 15.6 13.7 20.2 41.2 <0.001
Glucose, mmol/L 7.8 ± 3.5 7.7 ± 3.2 7.8 ± 3.5 8.4 ± 4.2 0.097 13.0 ± 5.3 12.6 ± 5.0 12.8 ± 4.8 14.1 ± 6.2 0.054
Previous medical history
Hypertension, % 36.4 36.9 38.7 42.6 0.001 55.6 53.1 53.9 64.0 0.062
Myocardial Infarction, % 7.3 6.5 6.8 9.6 0.005 6.7 9.7 11.9 17.7 0.003
Heart failure, % 1.0 1.2 2.0 5.0 <0.001 3.3 3.4 4.7 11.4 <0.001
Stroke, % 8.5 7.6 8.0 9.5 0.235 12.2 18.9 14.0 19.5 0.125
Therapeutic measures
PCI, % 10.4 12.4 11.7 9.2 0.024 16.7 20.0 21.8 11.8 0.023
Thrombolytic therapy, % 57.6 54.7 54.2 45.6 <0.001 53.3 45.1 40.4 43.0 0.068
Insulin, % 11.4 9.5 11.8 13.8 0.002 42.8 37.1 37.9 42.3 0.548
β-blockers, % 45.8 67.3 69.5 68.0 <0.001 42.8 73.1 66.8 68.0 <0.001
ACEI, % 68.3 74.3 73.1 71.8 <0.001 63.3 73.1 75.7 78.3 0.004
Lipid-lowering drugs, % 69.7 73.6 71.6 69.3 0.023 71.7 76.0 73.1 70.6 0.644

PCI, Percutaneous coronary intervention; ACEI, Angiotensin-converting enzyme inhibitors; P-values are given for the comparison of between the different quartiles of heart rate.

Han et al.

Han et al. BMC Cardiovascular Disorders 2012 12:104   doi:10.1186/1471-2261-12-104

Open Data